Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
- Conditions
- Adult T Acute Lymphoblastic LeukemiaAnn Arbor Stage II Adult Lymphoblastic LymphomaAnn Arbor Stage II Childhood Lymphoblastic LymphomaAnn Arbor Stage III Adult Lymphoblastic LymphomaAnn Arbor Stage III Childhood Lymphoblastic LymphomaAnn Arbor Stage IV Adult Lymphoblastic LymphomaAnn Arbor Stage IV Childhood Lymphoblastic LymphomaChildhood T Acute Lymphoblastic Leukemia
- Interventions
- Drug: CyclophosphamideDrug: BortezomibDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: DoxorubicinDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Hydrocortisone Sodium SuccinateDrug: IfosfamideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine SulfateDrug: Vincristine
- First Posted Date
- 2014-04-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 847
- Registration Number
- NCT02112916
- Locations
- 🇺🇸
Covenant Children's Hospital, Lubbock, Texas, United States
🇺🇸UMC Cancer Center / UMC Health System, Lubbock, Texas, United States
🇦🇺Monash Medical Center-Clayton Campus, Clayton, Victoria, Australia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BlinatumomabDrug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneOther: Pharmacological StudyDrug: EtoposideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MitoxantroneDrug: Mitoxantrone HydrochlorideRadiation: Radiation TherapyDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 669
- Registration Number
- NCT02101853
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 107
- Registration Number
- NCT02036489
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Barcelona, Spain
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionBiological: BlinatumomabProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideDrug: Leucovorin CalciumProcedure: Lumbar PunctureDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: PrednisoneBiological: RituximabDrug: VincristineDrug: Vincristine SulfateProcedure: X-Ray Imaging
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 488
- Registration Number
- NCT02003222
- Locations
- 🇺🇸
Banner North Colorado Medical Center, Greeley, Colorado, United States
🇺🇸Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸Banner McKee Medical Center, Loveland, Colorado, United States
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: dexamethasoneDrug: vincristine sulfateBiological: rituximabDrug: clofarabineDrug: cyclophosphamideDrug: etoposideBiological: aldesleukinDrug: pegaspargaseDrug: methotrexateDrug: mercaptopurineDrug: cytarabineDrug: mitoxantroneDrug: teniposideDrug: vinblastineBiological: natural killer cell infusionOther: laboratory biomarker analysisProcedure: allogeneic hematopoietic stem cell transplantationDrug: therapeutic hydrocortisoneDevice: CliniMACS
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01700946
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 570
- Registration Number
- NCT01503632
- Locations
- 🇺🇸
Advocate Lutheran General Hospital, Park Ridge, Illinois, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01451515
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
- Conditions
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 74
- Registration Number
- NCT01432145
- Locations
- 🇬🇧
Churchill Hospital, Oxford, United Kingdom
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsRecurrent Burkitt LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeBurkitt-Like Lymphoma With 11q AberrationRecurrent B Acute Lymphoblastic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedRefractory B Acute Lymphoblastic LeukemiaRefractory Burkitt LymphomaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 276
- Registration Number
- NCT01371630
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01358253
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.